- Home
- PINE vs VNDA Comparison
PINE vs VNDA Comparison
Compare PINE & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PINE
- VNDA
- Stock Information
- Founded
- PINE 2019
- VNDA 2002
- Country
- PINE United States
- VNDA United States
- Employees
- PINE N/A
- VNDA N/A
- Industry
- PINE Real Estate Investment Trusts
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- PINE Real Estate
- VNDA Health Care
- Exchange
- PINE Nasdaq
- VNDA Nasdaq
- Market Cap
- PINE 245.5M
- VNDA 237.9M
- IPO Year
- PINE 2019
- VNDA 2006
- Fundamental
- Price
- PINE $16.47
- VNDA $4.33
- Analyst Decision
- PINE Strong Buy
- VNDA Strong Buy
- Analyst Count
- PINE 9
- VNDA 2
- Target Price
- PINE $19.61
- VNDA $16.50
- AVG Volume (30 Days)
- PINE 90.9K
- VNDA 754.6K
- Earning Date
- PINE 04-24-2025
- VNDA 05-07-2025
- Dividend Yield
- PINE 6.80%
- VNDA N/A
- EPS Growth
- PINE N/A
- VNDA N/A
- EPS
- PINE 0.14
- VNDA N/A
- Revenue
- PINE $52,227,000.00
- VNDA $198,772,000.00
- Revenue This Year
- PINE $8.64
- VNDA $14.36
- Revenue Next Year
- PINE $4.58
- VNDA $44.53
- P/E Ratio
- PINE $117.64
- VNDA N/A
- Revenue Growth
- PINE 14.42
- VNDA 3.18
- 52 Week Low
- PINE $14.33
- VNDA $3.85
- 52 Week High
- PINE $19.42
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- PINE 54.69
- VNDA 43.42
- Support Level
- PINE $15.00
- VNDA $4.27
- Resistance Level
- PINE $15.99
- VNDA $4.46
- Average True Range (ATR)
- PINE 0.61
- VNDA 0.22
- MACD
- PINE 0.05
- VNDA 0.01
- Stochastic Oscillator
- PINE 69.75
- VNDA 54.55
About PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate company. It owns and operates a portfolio of single-tenant commercial properties. The company's portfolio is comprised of single-tenant retail and office properties located in or in close proximity to MSAs, growth markets and other markets in the United States. Their portfolio consists of One thirty eight net leased properties located in Hundred and four markets in thirty five states. The majority of the firm's revenue includes rental revenue derived from the ownership and leasing of property.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.